(Total Views: 429)
Posted On: 10/26/2019 2:15:09 PM
Post# of 149459
We will see if they get the deal done and financing finished to get the share price in the range needed to uplist.
Really otc is hindering the stock. Its amazing they have been able to get to this point, raising over 200M on otc. With a market cap of 125M, half of what they put into developing the drug, and this close to approval, I'm no longer concerned with shorting which happen after R/S.
I say option 1) get the deal done
2) Backup plan, R/S and uplist to a decent exchange to bring in institutional cash. Yeah that probably takes the 100x type of returns off the table with other otcs I have seen, but they shouldn't be hunting for cash this close to approval. Especially with mono p3 starting, leronlimb is is a billion dollar drug if mono happens. I don't believe BPs would argue that point, maybe on combo, but I doubt mono.
Lets see if they get option 1 done this week as NP said.
Really otc is hindering the stock. Its amazing they have been able to get to this point, raising over 200M on otc. With a market cap of 125M, half of what they put into developing the drug, and this close to approval, I'm no longer concerned with shorting which happen after R/S.
I say option 1) get the deal done
2) Backup plan, R/S and uplist to a decent exchange to bring in institutional cash. Yeah that probably takes the 100x type of returns off the table with other otcs I have seen, but they shouldn't be hunting for cash this close to approval. Especially with mono p3 starting, leronlimb is is a billion dollar drug if mono happens. I don't believe BPs would argue that point, maybe on combo, but I doubt mono.
Lets see if they get option 1 done this week as NP said.
(3)
(0)Scroll down for more posts ▼
